Perspectives in thoracic oncology:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Bremen [u.a.]
UNI-MED-Verl.
2012
|
| Ausgabe: | 1. ed. |
| Schriftenreihe: | UNI-MED science
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis Klappentext |
| Beschreibung: | 95 S. graph. Darst. |
| ISBN: | 9783837413724 9781848151918 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV040684505 | ||
| 003 | DE-604 | ||
| 005 | 20130201 | ||
| 007 | t | ||
| 008 | 130119s2012 d||| |||| 00||| eng d | ||
| 020 | |a 9783837413724 |9 978-3-8374-1372-4 | ||
| 020 | |a 9781848151918 |9 978-1-84815-191-8 | ||
| 035 | |a (OCoLC)826599152 | ||
| 035 | |a (DE-599)GBV733601472 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.99494061 |2 22//ger | |
| 084 | |a XH 5581 |0 (DE-625)152914:12989 |2 rvk | ||
| 245 | 1 | 0 | |a Perspectives in thoracic oncology |c [Oliver Gautschi ; Solange Peters. In collaboration with: Alex A. Adjei ...] |
| 250 | |a 1. ed. | ||
| 264 | 1 | |a Bremen [u.a.] |b UNI-MED-Verl. |c 2012 | |
| 300 | |a 95 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED science | |
| 650 | 0 | 7 | |a Thoraxkrebs |0 (DE-588)4274929-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Thoraxkrebs |0 (DE-588)4274929-3 |D s |
| 689 | 0 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Gautschi, Oliver |e Sonstige |4 oth | |
| 700 | 1 | |a Peters, Solange |e Sonstige |4 oth | |
| 700 | 1 | |a Adjei, Alex A. |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025510834&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025510834&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA |3 Klappentext |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-025510834 | ||
Datensatz im Suchindex
| _version_ | 1804149817798033408 |
|---|---|
| adam_text | Contents 11
Contents
Adjuvant
chemotherapy
in NSCLC 14
1.1.
Recent adjuvant chemotherapy trials
.....................................................14
1.2.
The LACE pooled analysis
................................................................15
1.3.
Which stages should benefit from adjuvant chemotherapy?
................................
IS
1.4.
The updated individual data-based meta-analysis
.........................................15
15.
Selection by age, histology or type of surgery
.............................................16
1.6.
Targeted therapies
.......................................................................16
1.7.
Prognostic/predictive
biomarkers
........................................................16
1Л.
Vaccines
.................................................................................17
1.9.
References
...............................................................................17
Customized chemotherapy
22
2.1. DNA
repair pathways and potential predictive markers of response to platinum-based
chemotherapy
...........................................................................22
2.2.
Current clinical data on customized approach to platinum-based chemotherapy
..........23
2.3.
Gemcitabine and pemetrexed as a platinum partner
......................................24
2.4.
What is the role of antimicrotubule agents in the perspective of customized chemotherapy
in NSCLC?
...............................................................................26
2.5.
References
...............................................................................27
Epidermal growth factor receptor tyrosine kinase inhibitors
30
3.1.
EGFRTKI as first line therapy
..............................................................30
3.2.
EGFR TKI as maintenance therapy
........................................................31
33.
EGFR TKI as second/third line therapy
....................................................32
3.4.
EGFR
ТЮ
as adjuvant therapy.
............................................................32
35.
Resistance to EGFR TKI
...................................................................33
ЗА.
References.
..............................................................................34
■■■I
■ - ■■ -■ ■ · - ■ · ■ ■ ■
44b
4.1.
Angtogenesis
............................................................................38
4X Anti-VEGF antibodies
....................................................................38
43.
VEGFtrap
................................................................................39
4.4.
Tyrosine kinase inhibitors
................................................................39
45.
Sorafenib
................................................................................*<>
4.6.
Sunrtirab
................................................................................40
4.7.
Vandetanib
..............................................................................40
4Ä
«BF1120
................................................................................40
4.9.
Cediranib
................................................................................40
4.ia Motesanib
...............................................................................41
4.11.
Axitinibandpazopanib
..................................................................41
4.1Z
Bèomarkers
..............................................................................41
«3.
References
..............................................·................................«
12 Contents
New
drug targets
44
5.1. ALK
as a target
...........................................................................44
5.2.
HGF/MET pathway
.......................................................................50
5.3.
SRC kinase
...............................................................................51
5.4.
IGF-1
R
pathway
..........................................................................51
5.5.
РІЗК
/Akt/mTOR
pathway
.................................................................53
5.6.
МАРК
pathway
..........................................................................54
5.7.
Histone deacetylase pathway
............................................................55
5.8.
Heat Shock Protein
90
(HSP90) pathway
..................................................56
5.9.
Sonic hedgehog pathway
................................................................57
5.10.
BCL-2
pathway
...........................................................................57
5.11.
JAK/STAT pathway
.......................................................................58
5.12.
LKB1/STK1
1
pathway
....................................................................58
5.13.
Immunotherapy for lung cancer
..........................................................59
5.14.
References
...............................................................................61
Small cell lung cancer (SCLC)
68
6.1.
Genetics and pathology
..................................................................68
6.2.
Clinical presentation
.....................................................................68
6.3.
Staging and evaluation
..................................................................69
6.4.
Management of LS-SCLC
.................................................................69
6.5.
Prophylactic cranial irradiation
...........................................................72
6.6.
Key ongoing clinical trials in LS-SCLC
.....................................................73
6.7.
Management of extensive stage SCLC
....................................................73
6.8.
Relapsed disease
.........................................................................74
6.9.
SCLC management: Past experience
-
Targeted therapeutics
..............................74
6.10.
SCLC management: Future directions
....................................................74
6.11.
References
...............................................................................75
m Thym ic
malignancies
80
7.1.
Staging and
histologie
classification
......................................................80
7.2.
Management of thymic malignancies
.....................................................81
7.3.
Ongoing clinical trials of systemic therapy in thymic malignancies
.........................83
7.4.
References
...............................................................................84
ВЦ
Malignant
pleural mesothelioma
-
The multimodality approach
88
■I Index
93
Perspectives
in Thoracic Oncology
Scientific progress in oncology is steadily
new perspectives for patients with thoracic malignan¬
cies, including targeted drugs and multimodality therapy.
In this book, leading experts provide us with the
cuflWlť
standard-of-care and new treatment approaches forpft-
tients with lung cancer, mesothelioma and thymoma.
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV040684505 |
| classification_rvk | XH 5581 |
| ctrlnum | (OCoLC)826599152 (DE-599)GBV733601472 |
| dewey-full | 616.99494061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99494061 |
| dewey-search | 616.99494061 |
| dewey-sort | 3616.99494061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 1. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01818nam a2200421 c 4500</leader><controlfield tag="001">BV040684505</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20130201 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">130119s2012 d||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783837413724</subfield><subfield code="9">978-3-8374-1372-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781848151918</subfield><subfield code="9">978-1-84815-191-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)826599152</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBV733601472</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99494061</subfield><subfield code="2">22//ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 5581</subfield><subfield code="0">(DE-625)152914:12989</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Perspectives in thoracic oncology</subfield><subfield code="c">[Oliver Gautschi ; Solange Peters. In collaboration with: Alex A. Adjei ...]</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen [u.a.]</subfield><subfield code="b">UNI-MED-Verl.</subfield><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">95 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED science</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Thoraxkrebs</subfield><subfield code="0">(DE-588)4274929-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Thoraxkrebs</subfield><subfield code="0">(DE-588)4274929-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gautschi, Oliver</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peters, Solange</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Adjei, Alex A.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025510834&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025510834&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Klappentext</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-025510834</subfield></datafield></record></collection> |
| id | DE-604.BV040684505 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T00:29:04Z |
| institution | BVB |
| isbn | 9783837413724 9781848151918 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-025510834 |
| oclc_num | 826599152 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 95 S. graph. Darst. |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | UNI-MED-Verl. |
| record_format | marc |
| series2 | UNI-MED science |
| spelling | Perspectives in thoracic oncology [Oliver Gautschi ; Solange Peters. In collaboration with: Alex A. Adjei ...] 1. ed. Bremen [u.a.] UNI-MED-Verl. 2012 95 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier UNI-MED science Thoraxkrebs (DE-588)4274929-3 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Thoraxkrebs (DE-588)4274929-3 s Pharmakotherapie (DE-588)4076066-2 s DE-604 Gautschi, Oliver Sonstige oth Peters, Solange Sonstige oth Adjei, Alex A. Sonstige oth Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025510834&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025510834&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA Klappentext |
| spellingShingle | Perspectives in thoracic oncology Thoraxkrebs (DE-588)4274929-3 gnd Pharmakotherapie (DE-588)4076066-2 gnd |
| subject_GND | (DE-588)4274929-3 (DE-588)4076066-2 |
| title | Perspectives in thoracic oncology |
| title_auth | Perspectives in thoracic oncology |
| title_exact_search | Perspectives in thoracic oncology |
| title_full | Perspectives in thoracic oncology [Oliver Gautschi ; Solange Peters. In collaboration with: Alex A. Adjei ...] |
| title_fullStr | Perspectives in thoracic oncology [Oliver Gautschi ; Solange Peters. In collaboration with: Alex A. Adjei ...] |
| title_full_unstemmed | Perspectives in thoracic oncology [Oliver Gautschi ; Solange Peters. In collaboration with: Alex A. Adjei ...] |
| title_short | Perspectives in thoracic oncology |
| title_sort | perspectives in thoracic oncology |
| topic | Thoraxkrebs (DE-588)4274929-3 gnd Pharmakotherapie (DE-588)4076066-2 gnd |
| topic_facet | Thoraxkrebs Pharmakotherapie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025510834&sequence=000003&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025510834&sequence=000004&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT gautschioliver perspectivesinthoraciconcology AT peterssolange perspectivesinthoraciconcology AT adjeialexa perspectivesinthoraciconcology |